- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.08. | Biohaven trashes troriluzole in OCD after asset bungles phase 3 trial | ||
| 12.08. | ARPA-H data chief departs over disagreement with mRNA vaccine rollback | ||
| 12.08. | PureTech launches Celea Therapeutics to develop highly touted lung disease candidate | ||
| 12.08. | Bayer picks Kumquat for KRAS collaboration, with $1.3B on offer if pact bears fruit | ||
| 12.08. | Novartis' blood disorder readout earns Novartis 3rd phase 3 win for ianalumab this week | ||
| 12.08. | Vaxart seeks answers as BARDA funding for stop-start vaccine project dries up again | ||
| 11.08. | Novel RNA biotech winds down after missing milestone in Bayer pact | ||
| 11.08. | Expedition inks $645M pact to pocket Fosun's lung disease asset in knapsack | ||
| 11.08. | Cancer vaccine's 'narrow' phase 3 fail won't stop IO heading to FDA | ||
| 11.08. | Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed | ||
| 08.08. | Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application | ||
| 08.08. | Gilead culls Novo-partnered MASH candidate and 2 cancer assets | ||
| 08.08. | Bicycle lays off 25% of workforce as Genentech rides away from R&D pact | ||
| 07.08. | Strand's Big Pharma-backed series B brings in $153M to advance mRNA tumor drugs | ||
| 07.08. | Eli Lilly shakes up pain pipeline as part of quarterly R&D clearout | ||
| 07.08. | Minghui raises $131M 'pre-IPO' round to bankroll JAK inhibitor launch, ADC trials | ||
| 07.08. | Gilead hands back one Arcus cancer candidate from $725M deal | ||
| 07.08. | Keros shakes up leadership structure to go all in on DMD drug | ||
| 06.08. | NIH broke law by withholding Congress-approved funding: GAO | ||
| 06.08. | Flagship Pioneering's Alltrna sheds staff as it readies for clinical debut | ||
| 06.08. | Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria's navenibart in Japan | ||
| 06.08. | Contineum reroutes pipeline, funneling cash from MS to lung disease as it eyes showdown with BMS | ||
| 06.08. | Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets | ||
| 06.08. | Novo Nordisk drops 2 obesity drugs as part of major pipeline clearout | ||
| 05.08. | BioNTech cuts 90 more US jobs as the drugmaker hones pipeline focus |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .